News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
788,264 Results
Type
Article (60217)
Company Profile (413)
Press Release (727617)
Multimedia
Podcasts (138)
Webinars (19)
Section
Business (222423)
Career Advice (2964)
Deals (38350)
Drug Delivery (129)
Drug Development (87906)
Employer Resources (196)
FDA (17618)
Job Trends (16539)
News (377711)
Policy (36853)
Tag
Academia (2963)
Academic (2)
Accelerated approval (15)
Adcomms (33)
Allergies (111)
Alliances (54854)
ALS (127)
Alzheimer's disease (1616)
Antibody-drug conjugate (ADC) (194)
Approvals (17596)
Artificial intelligence (396)
Autoimmune disease (37)
Automation (22)
Bankruptcy (393)
Best Places to Work (12421)
BIOSECURE Act (21)
Biosimilars (141)
Biotechnology (263)
Bladder cancer (109)
Brain cancer (44)
Breast cancer (416)
Cancer (3319)
Cardiovascular disease (268)
Career advice (2497)
Career pathing (34)
CAR-T (218)
CDC (43)
Cell therapy (584)
Cervical cancer (27)
Clinical research (72234)
Collaboration (1203)
Company closure (4)
Compensation (804)
Complete response letters (43)
COVID-19 (2895)
CRISPR (71)
C-suite (435)
Cystic fibrosis (123)
Data (3416)
Decentralized trials (2)
Denatured (47)
Depression (84)
Diabetes (388)
Diagnostics (6941)
Digital health (25)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (169)
Drug pricing (166)
Drug shortages (35)
Duchenne muscular dystrophy (174)
Earnings (93100)
Editorial (51)
Employer branding (25)
Employer resources (167)
Events (125933)
Executive appointments (938)
FDA (19704)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1066)
Gene editing (153)
Generative AI (33)
Gene therapy (471)
GLP-1 (967)
Government (5138)
Grass and pollen (7)
Guidances (326)
Healthcare (20522)
HIV (45)
Huntington's disease (32)
IgA nephropathy (48)
Immunology and inflammation (198)
Immuno-oncology (17)
Indications (44)
Infectious disease (3099)
Inflammatory bowel disease (170)
Inflation Reduction Act (13)
Influenza (78)
Intellectual property (147)
Interviews (568)
IPO (17444)
IRA (59)
Job creations (4533)
Job search strategy (2063)
Kidney cancer (15)
Labor market (63)
Layoffs (596)
Leadership (28)
Legal (9167)
Liver cancer (88)
Longevity (12)
Lung cancer (465)
Lymphoma (237)
Machine learning (16)
Management (64)
Manufacturing (493)
MASH (112)
Medical device (14486)
Medtech (14498)
Mergers & acquisitions (21692)
Metabolic disorders (1007)
Multiple sclerosis (108)
NASH (23)
Neurodegenerative disease (165)
Neuropsychiatric disorders (46)
Neuroscience (2437)
NextGen: Class of 2025 (7317)
Non-profit (4974)
Now hiring (53)
Obesity (509)
Opinion (292)
Ovarian cancer (109)
Pain (138)
Pancreatic cancer (138)
Parkinson's disease (207)
Partnered (24)
Patents (363)
Patient recruitment (224)
Peanut (55)
People (63996)
Pharmaceutical (112)
Pharmacy benefit managers (25)
Phase I (22403)
Phase II (31603)
Phase III (23689)
Pipeline (2302)
Policy (268)
Postmarket research (3050)
Preclinical (9785)
Press Release (72)
Prostate cancer (162)
Psychedelics (46)
Radiopharmaceuticals (276)
Rare diseases (565)
Real estate (6859)
Recruiting (75)
Regulatory (25610)
Reports (62)
Research institute (2629)
Resumes & cover letters (465)
Rett syndrome (11)
RNA editing (12)
RSV (61)
Schizophrenia (112)
Series A (178)
Series B (130)
Service/supplier (19)
Sickle cell disease (72)
Special edition (22)
Spinal muscular atrophy (162)
Sponsored (36)
Startups (4075)
State (2)
Stomach cancer (17)
Supply chain (89)
Tariffs (81)
The Weekly (89)
Vaccines (950)
Venture capital (62)
Weight loss (348)
Women's health (51)
Worklife (20)
Date
Today (93)
Last 7 days (495)
Last 30 days (2511)
Last 365 days (32973)
2025 (21089)
2024 (37387)
2023 (42301)
2022 (53530)
2021 (58279)
2020 (57108)
2019 (50504)
2018 (38345)
2017 (35485)
2016 (35734)
2015 (41774)
2014 (35919)
2013 (31368)
2012 (33416)
2011 (34027)
2010 (32691)
Location
Africa (1011)
Alabama (68)
Alaska (7)
Arizona (275)
Arkansas (14)
Asia (46354)
Australia (8055)
California (8361)
Canada (2579)
China (777)
Colorado (357)
Connecticut (368)
Delaware (228)
Europe (101953)
Florida (1269)
Georgia (290)
Hawaii (3)
Idaho (64)
Illinois (736)
India (37)
Indiana (405)
Iowa (18)
Japan (255)
Kansas (117)
Kentucky (32)
Louisiana (19)
Maine (65)
Maryland (1147)
Massachusetts (6313)
Michigan (285)
Minnesota (516)
Mississippi (4)
Missouri (107)
Montana (32)
Nebraska (25)
Nevada (95)
New Hampshire (74)
New Jersey (2323)
New Mexico (31)
New York (2310)
North Carolina (1262)
North Dakota (10)
Northern California (3714)
Ohio (260)
Oklahoma (17)
Oregon (42)
Pennsylvania (1795)
Puerto Rico (18)
Rhode Island (41)
South America (1392)
South Carolina (42)
South Dakota (1)
Southern California (3165)
Tennessee (136)
Texas (1300)
United States (31199)
Utah (250)
Virginia (222)
Washington D.C. (81)
Washington State (714)
West Virginia (4)
Wisconsin (87)
788,264 Results for "sonoma pharma formerly known as oculus innovative sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results
August 8, 2025
·
11 min read
Press Releases
Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains
August 13, 2025
·
3 min read
Press Releases
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results
June 17, 2025
·
13 min read
Venture capital
Building Pharma’s Farm System: Eli Lilly, Boehringer Ingelheim, More Invest in the Future
While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and venture funds to uncover cutting-edge scientific trends, determine their future focus points and even carve out a niche in an emerging geographical hotspot.
August 6, 2025
·
5 min read
·
Heather McKenzie
Business
New Jersey’s Life Sciences Scene Continues Expanding Beyond Big Pharma
Known as the home of big-name companies including Johnson & Johnson, New Jersey has become a destination for more and more small and midsize life sciences businesses. Choose New Jersey, Grace Therapeutics and Onyx Equities executives discuss the state’s life sciences scene.
April 10, 2025
·
6 min read
·
Angela Gabriel
Press Releases
Sonoma Biotherapeutics Announces Poster Presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress
June 5, 2025
·
1 min read
Job Trends
Amidst Industry Challenges, 85% of Pharmas Increase Investment in AI
A new report found that 85% of pharma respondents are increasing their artificial intelligence investments, and 70% see AI as an immediate priority. Two experts discuss how biopharmas are implementing and adopting AI, including their increased use of external help with the process.
July 31, 2025
·
4 min read
·
Angela Gabriel
Press Releases
Sonoma Biotherapeutics Appoints Rajesh Krishnan, Ph.D., as Chief Technical Officer
May 13, 2025
·
2 min read
Business
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
NovaBay Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova branded products by Sonoma in the European Union.
January 9, 2024
·
6 min read
Earnings
AstraZeneca CEO Says World ‘Needs to Share’ in Global Pharma R&D
Pascal Soriot’s comments came during AstraZeneca’s Q2 earnings call in regard to President Donald Trump’s newly announced European pharma tariffs. The company also announced estimate-beating earnings, with its cancer portfolio driving earnings despite clinical roadblocks.
July 29, 2025
·
3 min read
·
Tristan Manalac
1 of 78,827
Next
